Indivior PLC Appointment of Chief Financial Officer (0258G)
November 20 2020 - 05:30AM
UK Regulatory
TIDMINDV
RNS Number : 0258G
Indivior PLC
20 November 2020
Indivior PLC - Appointment of Chief Financial Officer
Slough, UK, and Richmond, VA, November 20, 2020 - The Board of
Directors of Indivior PLC are pleased to announce the appointment
of Ryan Preblick as Chief Financial Officer and Executive Director
with immediate effect.
Ryan has been serving as Interim Chief Financial Officer since
June 2020 and has been in financial leadership roles since joining
Indivior in 2012. Prior to his appointment as Interim Chief
Financial Officer in June 2020, Ryan was Senior Vice President,
Global Financial Planning and Analysis Commercial Operations. This
role included overseeing all key financial management, analysis and
reporting elements of the Group's global business. Prior to that,
Ryan was Vice President, US Finance with responsibility overseeing
all financial areas of the US business, the Group's largest
business, including management, planning, analysis and reporting,
government pricing and managed care contracting operations.
Ryan started his career in corporate finance at Honeywell
International and then spent twelve years at Altria Company
(including Philip Morris USA) in finance leadership roles of
increasing responsibility working with Treasury, Financial Planning
& Analysis, Market Analytics, Supply Chain and Brand Decision
Support. Ryan holds a BS in Finance from Penn State University and
an MBA from the University of Richmond.
Comment by Mark Crossley, Chief Executive Officer
Ryan has proven to be a highly capable leader of our finance
organization and has performed strongly in his role as Interim
Chief Financial Officer. The Board and I are delighted to confirm
his appointment as Chief Financial Officer and Executive
Director.
The Company confirms there is no further information to be
disclosed pursuant to LR 9.6.13 in connection with Ryan Preblick's
appointment.
About Indivior
Indivior is a global pharmaceutical company working to help
change patients' lives by developing medicines to treat addiction
and serious mental illnesses. Our vision is that all patients
around the world will have access to evidence-based treatment for
the chronic conditions and co-occurring disorders of addiction.
Indivior is dedicated to transforming addiction from a global human
crisis to a recognized and treated chronic disease.
Building on its global portfolio of opioid dependence
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of
addiction, including alcohol use disorder. Headquartered in the
United States in Richmond, VA, Indivior employs more than 700
individuals globally and its portfolio of products is available in
over 40 countries worldwide. Visit www.indivior.com to learn more.
Connect with Indivior on LinkedIn by visiting
www.linkedin.com/company/indivior .
Investor Contact :
Jason Thompson, Indivior
Vice President, Investor Relations
+1 804-402-7123
Jason.Thompson@indivior.com
Media Contacts :
UK
Tulchan Communications
+44 207-353-4200
US
IndiviorMediaContacts@indivior.com
+1 804-594-0836
-ends-
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABMBMTMTJTBBM
(END) Dow Jones Newswires
November 20, 2020 06:30 ET (11:30 GMT)
Indivior (LSE:INDV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Indivior (LSE:INDV)
Historical Stock Chart
From Mar 2023 to Mar 2024